Use of ceftazidime in severe Gram-negative infections--a preliminary study.
Ceftazidime was used to treat ten patients with serious Gram-negative bacillary infections. Seven patients had bronchopulmonary infections and three had urinary tract infections. In addition three patients were bacteraemic. Causative agents were: Pseudomonas aeruginosa 4, Escherichia coli 2, Proteus species 2, and Klebsiella pneumoniae 2. Doses ranged between 2 and 6 g/day. Nine out of ten patients responded favourably to ceftazidime (cure or improvement). Colonization with ceftazidime-resistant strains occurred in three cases. No evidence of nephrotoxicity was noted.
St. Pierre University Hospital, rue Haute, 322, 1000 Brussels, Belgium.
N
N
Clumeck
Y
Y
Vanlaethem
B
B
Gordts
N
N
Jaspar
J P
JP
Butzler
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002442:Ceftazidime / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology; D055815:Young Adult
D000900:Anti-Bacterial Agents; D002442:Ceftazidime